Establishment Of Animal Model Of Tumor Recurrence And Metastasis And The Effects Of New Biotherapeutics On Tumor Recurrence And Metastasis

Doctors have many choices to deal with the cancer patients at the first time of diagnosis. Surgery, chemotherapy, radiotherapy, biotherapy, Traditional Chinese Medicine and combined therapy are among them. So cancer now is not a 'conviction of death' any more. But cancer recurrence and metastasis is still the haunting ghost.Tumor recurrence means the small number of tumor cells that was leftover after primary treatment begins to proliferate continually and form a new tumor mass at the original site of tumor(local). If the mass is formed in organs or tissues that is separated from the original one, the process is called metastasis. Currently, tumor recurrence is attracting more and more attention of oncologists. Papers about the site of recurrence, the rate of recurrence, the prognostic marker of recurrence and the treatment of recurrence are accumulating. There are few animal models about tumor recurrence and metastasis.Inoculating murine uterus carcinomaU14 cells (6×10~5/0.05ml) into the footpad of 615 mice, we established the animal model of tumor recurrence and metastasis. The primary tumor was removed by amputation at 3d, 6d, 9d, 12d and 15d; ten mice each group/day. All the mice were sacrificed 25 days after inoculation. The local recurrence rate for each group is 40%, 50%, 50%, 60% and 90% accordingly. The metastasis rate is 40%, 37.5%, 50%, 70%, and 90% accordingly. So remove the primary tumor between 9d to 12d, the animal model is suitable for the study of tumor recurrence and metastasis and experimental therapy.Tumor vaccines are entering a new phase of popularity, in part because of the recognition of when a therapeutic vaccine is most effective and the identification of appropriate target antigens. In this area, major progress has been made by using dendritic cell or even naked DNA-based vaccines. The generation of new tools such as HLA-tetramer complexes now allows researchers to monitor more closely the expansion of peptide-specific T cells under the process of vaccination. On the basis of these advances, a couple of vaccine trials have been performed that have increases our knowledge of vaccine development and provided indications that the concept of tumor-specific vaccination might be valid. However, we are still at the beginning of this process and...